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E D I T O R I A L
A call to action for fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) has become the most com-
mon chronic liver disease worldwide, affects nearly 30% of adults 
in the general population1 and approximately 70% of those with 
obesity and type 2 diabetes (T2DM)2 and is already among the top 
indications for liver transplantation in most high- income countries. 
In the last decade, it has become evident that NAFLD is a multisys-
temic disease,3 which is associated not only with adverse hepatic 
outcomes but also with relevant extra- hepatic complications, such 
as T2DM,4 cardiovascular disease (CVD),5 chronic kidney disease 
(CKD)6 and specific extra- hepatic cancers.7
In 2020, a panel of international experts has proposed the change 
of the terminology from NAFLD to metabolic associated fatty liver 
disease (MAFLD), as well as an update in the definition of fatty liver 
disease.8 Specifically, the diagnosis of MAFLD can be supported by 
the presence of hepatic steatosis, as detected by serum biomarker 
scores, imaging methods or histology, in individuals with overweight/
obesity, T2DM or multiple metabolic alterations. Given these prem-
ises, fatty liver disease is gaining more and more attention in both 
clinical and basic research. In the last months, high- quality data have 
been published on Liver International on this topic, providing some 
answers and raising new research questions. The results of these 
studies may have also important public health implications.
1  | NAFLD VERSUS MAFLD: WHERE ARE 
WE?
From the publication of the proposed novel MAFLD criteria,8 some 
observational studies have compared MAFLD and NAFLD criteria 
for the detection of the hepatic and extra- hepatic complications of 
fatty liver, providing initial but yet not definitive answers, as recently 
reviewed.9,10 Indeed, some but not all studies showed that MAFLD 
were better than NAFLD criteria at discriminating the risk of espe-
cially liver- related complications. In this regard, in a recent study in-
volving 1710 US participants (mean age 46 years; 51% were women; 
mean body mass index 28 kg/m2) from the 2017- 2018 NHANES co-
hort, Ciardullo and Perseghin reported that for NAFLD and MAFLD, 
the weighted prevalence was 37% and 39%, respectively, and risk 
of advanced liver fibrosis estimated by elastography was 7.5% and 
7.4%, respectively. These findings are partly different from those 
provided by Lin et al,11 who have used data from the 1988- 1994 
NHANES, and by other authors.12,13 In this context, we want to un-
derline three specific points. First, observational studies available 
so far11- 13 largely differ for participants characteristics, study de-
sign and setting. Consequently, they are difficult to compare, and 
notably, the MAFLD criteria may work differently, depending on 
the prevalence of different features of dysmetabolism and at- risk 
alcohol intake. Second, the detection of steatosis was performed by 
different methods, including ultrasonography, magnetic resonance 
imaging and liver biopsy. Third, non- invasive markers of liver fibrosis, 
such as FIB- 4 and NAFLD fibrosis score, have limited accuracy, and 
have yet not been validated in patients with MAFLD. In this regard, 
in an observational study involving nearly 420 consecutive Asian pa-
tients with biopsy- proven MAFLD, Wu et al reported that the FIB- 4 
cut- off of 1.3 had only 58% sensitivity and 74% specificity for ad-
vanced fibrosis.14 Furthermore, given that the NAFLD fibrosis score 
considers the presence of diabetes, it tends to overestimate fibrosis 
risk in patients with this condition.
2  | T WO IS WORSE THAN ONE
Another open question is to understand whether in patients with 
fatty liver, the risk of hepatic and extra- hepatic complications is fur-
ther increased by the coexistence of different risk factors, such as 
at- risk alcohol intake and features of dysmetabolism. In the last dec-
ade, observational studies have demonstrated that the simultaneous 
presence of metabolic syndrome and excessive alcohol consumption 
is independently associated with mortality. For instance, in a cohort 
of nearly 4300 individuals with fatty liver followed for 20 years, 
Younossi et al reported that metabolic syndrome and excessive al-
cohol consumption were associated with mortality and that the ef-
fect of excessive alcohol use was specifically detected in individuals 
with dysmetabolism.15 By contrast, in the NHANES cohort including 
8162 participants (56% with NAFLD), Hajifathalian et al showed that, 
among individuals with NAFLD, modest alcohol consumption (0.5- 
1.5 drinks/day) was associated with a decrease in all- cause mortality 
whereas high alcohol consumption (i ≥ 1.5 drinks/day) with increased 
mortality, over a mean follow- up of 12 years.16 Scarce information is 
however available on the impact of dysmetabolism on liver fibrosis in 
patients with fatty liver stratified by alcohol consumption.
In a population- based study enrolling 1760 Spanish individuals 
(263 were former drinkers, and 1497 were current drinkers at the 
time of the study), Pose et al now report that metabolic syndrome 
was associated with a nearly four- fold higher risk of liver fibrosis 
(stiffness ≥8 kPa) in individuals with alcohol consumption, pointing 
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out the additive adverse effect of the metabolic and toxic compo-
nent of liver fibrosis.17 These findings support the notion that a 
stringent control of metabolic risk factors is mandatory for the man-
agement of individuals with alcohol- related liver disease. In addition, 
given that there is now convincing evidence demonstrating that 
the ‘safe’ levels of alcohol consumption are near zero,18 physicians 
should encourage all patients with fatty liver to abstain from alcohol 
(impractical though it may seem).
3  | SARCOPENIA AND NAFLD: THERE IS 
MORE
Another emerging predictor of poor prognosis in individuals with 
NAFLD is sarcopenia. Some cross- sectional studies and a meta- 
analysis19 have documented that sarcopenia is associated with 
NAFLD, even after adjustment for metabolic confounders. However, 
information regarding the direct impact of sarcopenia on morbid-
ity and mortality in patients with NAFLD is still scarce. By analysing 
11 065 US individuals from the NHANES III (34% with NAFLD on ul-
trasonography), Kim et al now showed that, during a median follow-
 up of 23 years, sarcopenia (as diagnosed by bioelectrical impedance) 
was associated with all- cause mortality in individuals with NAFLD 
(HR 1.44, 95% CI 1.16- 1.80) but not in those without liver involve-
ment.20 In addition, individuals with both sarcopenia and NAFLD 
had a higher risk for all- cause mortality (HR 1.28, 95% CI 1.06- 
1.55), when compared to those without sarcopenia and NAFLD.20 
Interestingly, sarcopenia was significantly associated with a higher 
risk for cancer- (HR 1.49, 95% CI 1.01- 2.20) and diabetes- (HR 4.94, 
95% CI 1.70- 14.38) related mortality in patients with NAFLD only.20 
These findings support the notion that, in NAFLD patients with 
sarcopenia, physical activity and dietary interventions aimed to in-
crease skeletal muscle mass may improve clinical outcomes.21
4  | NAFLD AND C VD: WHAT’S NE W?
The association between NAFLD and CVD has extensively been 
studied in the last two decades,22 clearly documenting that the most 
common cause of death among patients with NAFLD is cardiovascu-
lar events.23 The magnitude of increase in cardiovascular risk seems 
to be proportional to the severity of NAFLD.24 In a recent nation-
wide, age- and sex- matched cohort study enrolling 10 568 Swedish 
individuals in with biopsy- confirmed NAFLD (11% with T2DM at 
baseline) and 49 925 controls (3% with T2DM), Simon et al reported 
that mortality rates from CVD progressively increased from simple 
steatosis (HR 1.25, 95% CI 1.16- 1.35) to NASH (HR 1.66, 95% CI 
1.38- 2.01), noncirrhotic fibrosis (HR 1.40, 95% CI 1.17- 1.69) and 
cirrhosis (HR 2.11, 95% CI 1.63- 2.73), over a median follow- up of 
14 years.24
Two novel studies have now been published. In a longitudinal 
study of 3718 consecutive patients with previous myocardial infarc-
tion, Cao et al reported that, compared to those with low values of 
non- invasive markers of liver fibrosis, those with high values had a 
higher risk of incident fatal and nonfatal cardiovascular events, over 
a mean follow- up of 4 years.25 Importantly, the incorporation of 
non- invasive markers of liver fibrosis in a prediction model including 
classical CVD risk factors improved the prediction for incident car-
diovascular events.25 These data suggest that liver fibrosis may be 
considered as a novel independent predictor for fatal and nonfatal 
cardiovascular events.
Unfortunately, cardiovascular risk management is still subopti-
mal in daily clinical practice for NAFLD patients. Using a national 
digestive disease specialists survey on cardiovascular risk man-
agement in Spanish hospitals, Iruzubieta et al documented that, 
although ∼80% clinicians were aware that NAFLD is a strong predic-
tor of cardiovascular events, approximately only one- fifth of respon-
dents performed an elementary physical examination to address the 
cardiovascular risk, nearly 50% spent less than 5 min providing life-
style advice and approximately 52% did not start any drug treatment 
after a recent diagnosis of any CVD.26 Given the strong evidence 
in support,3,5,23,27 this attitude may be no longer justifiable. In this 
regard, it is important to remember that, in a post hoc analysis of 
GREACE randomized controlled study enrolling 437 patients with 
moderately abnormal liver tests at baseline due NAFLD, Athyros 
et al documented that NAFLD patients who received atorvastatin 
had significantly reduced cardiovascular morbidity and a decrease 
in alanine aminotransferase (ALT) levels without significant liver- 
related adverse events.28
Statin treatment was also associated with less severe steatosis, 
inflammation and fibrosis in patients with NAFLD,29,30 although 
carriage of the I148 M PNPLA3 risk variant, the main genetic deter-
minant of progressive liver disease31 may limit beneficial effects.29 
In a recent observational study of 11 593 409 individuals from the 
National Health Information Database of the Republic of Korea 
(712 262 of whom had NAFLD), Lee et al showed that the statin 
use was independently associated with a reduced risk of NAFLD (OR 
0.66, 95% CI 0.65- 0.67), as well as with a reduced risk of significant 
liver fibrosis (OR 0.43, 95% CI 0.42- 0.44).30 Similar considerations 
might be done for specific antihypertensive agents, such as renin- 
angiotensin axis modulators.32,33 At present, there are still few data 
on the effects of various antiplatelet agents on liver fibrosis in pa-
tients with NAFLD.34
Large randomized controlled trials focused on treatments for 
liver disease with systematic evaluation of cardiovascular outcomes 
are still needed to establish a causal association between fatty liver 
disease and CVD. For now, there is already ample evidence support-
ing the early and aggressive treatment of the coexisting cardiometa-
bolic comorbidities in all patients with NAFLD.
5  | KE Y MESSAGES
The current evidence supports the notion that NAFLD is a mul-
tisystem disease,3 with dramatic consequences not only from 
the clinical point of view but also from the economic point of 
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view.35 In this regard, recently, Schattenberg et al clearly docu-
mented a dramatic economic impact of nonalcoholic steatohepa-
titis (NASH) in adults living in five European countries, namely, 
France, Germany, Italy, Spain and the United Kingdom.35 Hence, 
earlier diagnosis and care of NAFLD and its consequences may 
contribute to reduce future healthcare impact and costs. In doing 
this, a ‘liver- centric’ approach to NAFLD is no longer sufficient. 
Unfortunately, the awareness of this is not yet deep- rooted 
among clinicians.26 An individualized and holistic management of 
NAFLD/MAFLD patients with relevant metabolic comorbidities 
(such as T2DM, obesity, dyslipidemia, hypertension and CVD) by 
a team of experts, including not only hepatologists but, starting 
from general practitioners, involve also endocrinologists, intern-
ists, cardiologists and pathologists, will be key and increasingly 
necessary (Figure 1). Such effort might provide the basis for a 
more rational approach to manage fatty liver disease and its con-
sequences, thereby attenuating its global burden and economic 
impact.
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